Clinical Trials Browser

Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant

Prostatic Neoplasms, Castration-Resistant

Metastatic Castration-sensitive Prostate Cancer

Prostatic Neoplasms

Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant

Prostatic Neoplasms

Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Neoplasm Metastasis, Prostatic Neoplasms

Newly Diagnosed Oligometastatic Prostate Cancer

Metastatic Castration Resistant Prostate Cancer

Prostatic Neoplasms

Prostatic Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Castration-resistant Prostate Cancer

Adenocarcinoma, Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant

Prostatic Neoplasms

Neoplasm Metastasis, Prostatic Neoplasms

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

Prostatic Neoplasms

Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms

Prostatic Neoplasms

Metastatic Castration Resistant Prostate Cancer

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostate Cancer Metastatic

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Clinical Trials

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

QUEST

MAGNITUDE

AMPLITUDE

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

CELLO-1

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

CONTACT-02

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

PANTHER

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

TRITON3

Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

KEYLYNK-010

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

CYCLONE 2

Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer

Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)

Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

PLATO

RAMP

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer

Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Restore

CARD

Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

STAAR

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy